Phase 3 clinical trial of IVMED-80
Latest Information Update: 30 Oct 2020
At a glance
- Drugs Copper sulfate (Primary)
- Indications Keratoconus
- Focus Therapeutic Use
- Sponsors iVeena Delivery Systems
- 30 Oct 2020 New trial record
- 27 Oct 2020 According to an iVeena media release, following recent discussions with the FDA, it will enter Phase 3 registration studies and upon market approval be granted 7-years regulatory exclusivity.